Interim fluorine-18 fluorodeoxyglucose positron emission tomography forearly metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma

Patrizia Giannatempo, Alessandra Alessi, Rosalba Miceli, Daniele Raggi, Elena Farè, Nicola Nicolai, Gianluca Serafini, Barbara Padovano, Luigi Piva, Davide Biasoni, Tullio Torelli, Mario Catanzaro, Silvia Stagni, Massimo Maffezzini, Luigi Mariani, Alessandro M. Gianni, Guru Sonpavde, Roberto Salvioni, Andrea Necchi, Flavio Crippa

Research output: Contribution to journalArticlepeer-review

Abstract

Fluorine-18 fluorodeoxyglucose positron emission tomography is increasingly used by many centers for staging and response assessment of metastatic transitional cell carcinoma. We prospectively evaluated 31 patients undergoing metabolic restaging after only 2 cycles of first-line chemotherapy (PET2). Early metabolic response was associated with patient outcome. The aim was to provide a proof of principle for a risk-adapted approach based on PET2 that may guide new trial design for early-recognized unresponsive patients.

Original languageEnglish
Pages (from-to)433-439
Number of pages7
JournalClinical Genitourinary Cancer
Volume12
Issue number6
DOIs
Publication statusPublished - 2014

Keywords

  • Imaging biomarkers
  • Metabolic response
  • Positron emission tomography
  • Transitional cell carcinoma
  • Urothelial cancer

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Interim fluorine-18 fluorodeoxyglucose positron emission tomography forearly metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma'. Together they form a unique fingerprint.

Cite this